2BO
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more
2BO (2BO) - Total Assets
Latest total assets as of September 2025: €12.41 Million EUR
Based on the latest financial reports, 2BO (2BO) holds total assets worth €12.41 Million EUR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
2BO - Total Assets Trend (2021–2024)
This chart illustrates how 2BO’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
2BO - Asset Composition Analysis
Current Asset Composition (December 2024)
2BO's total assets of €12.41 Million consist of 84.4% current assets and 15.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 54.6% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how 2BO's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 2BO's current assets represent 84.4% of total assets in 2024, an increase from 72.1% in 2021.
- Cash Position: Cash and equivalents constituted 54.6% of total assets in 2024, up from 17.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
2BO Competitors by Total Assets
Key competitors of 2BO based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
2BO - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - 2BO generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - 2BO is currently not profitable relative to its asset base.
2BO - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.31 | 0.40 | 0.40 |
| Quick Ratio | 1.31 | 0.40 | 0.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.71 Million | € -8.09 Million | € -8.09 Million |
2BO - Advanced Valuation Insights
This section examines the relationship between 2BO's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 31.53 |
| Latest Market Cap to Assets Ratio | 0.93 |
| Asset Growth Rate (YoY) | -25.0% |
| Total Assets | €6.72 Million |
| Market Capitalization | $6.23 Million USD |
Valuation Analysis
Near Book Valuation: The market values 2BO's assets close to their book value ( 0.93x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: 2BO's assets decreased by 25.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 2BO (2021–2024)
The table below shows the annual total assets of 2BO from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €6.72 Million | -25.02% |
| 2023-12-31 | €8.97 Million | +945.17% |
| 2022-12-31 | €858.04K | -53.48% |
| 2021-12-31 | €1.84 Million | -- |